07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

16/18 genotyping HPV test regulatory update

The National Comprehensive Cancer Network (NCCN) updated its clinical practice guidelines in oncology for cervical cancer screening to recommend that a HPV 16/18 DNA test should complement cervical cancer screening methods, such as regular Pap...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Clinical News

16/18 genotyping HPV test regulatory update

FDA approved a PMA from Hologic for its Cervista HPV 16/18 test as an adjunct with the Cervista HPV HR test to detect HPV types 16 and 18 infection in women ages 30 and...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

16/18 genotyping HPV test diagnostic data

Data from a study showed that the Cervista 16/18 test had a negative predictive value of 99.5% for grade 3 cervical intraepithelial neoplasia (CIN3) and 97.7% for CIN2/3. Data were presented at the European Research...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

Hologic, Third Wave deal

Hologic will acquire fellow diagnostics company Third Wave for $11.25 per share, or about $580 million in cash. The price is a 7% premium to Third Wave’s close of $10.50 on June 6, the last...
01:28 , Jun 10, 2008 |  BC Extra  |  Top Story

Hologic to acquire Third Wave

Hologic (NASDAQ:HOLX) will acquire fellow diagnostics company Third Wave (NASDAQ:TWTI) for $11.25 per share, or about $580 million in cash. The price is a 7% premium to Third Wave's close of $10.50 on Friday, the...
07:00 , May 5, 2008 |  BC Week In Review  |  Clinical News

14-type high-risk HPV test regulatory update

Third Wave submitted a PMA to FDA for its 14-type high-risk HPV test for use in conjunction with a Pap test to detect 14 types of high-risk human papillomavirus (HPV) in women ages 30 and...
07:00 , May 5, 2008 |  BC Week In Review  |  Clinical News

16/18 genotyping HPV test regulatory update

Third Wave submitted a PMA to FDA for its 16/18 genotyping HPV test to detect human papillomavirus (HPV) types 16 and 18. The company expects to launch a single instrument that utilizes the test and...
07:00 , May 5, 2008 |  BioCentury  |  Finance

Ebb & Flow

Publicly quoted European biotechs, beaten down by tough capital market conditions, will take some comfort from last week's news that the Netherlands' largest pension group is committed to increasing its focus on small-cap life science...
01:09 , Apr 29, 2008 |  BC Extra  |  Company News

Third Wave submits PMAs for HPV tests

Third Wave (NASDAQ:TWTI) submitted two PMAs to FDA for its 14-type high-risk HPV test to detect 14 types of high-risk HPV and its 16/18 genotyping HPV test to detect HPV types 16 and 18. On...